16Jan 2023
A co‐formulation of pramlintide and insulin A21G (ADO09) improves post‐prandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes

A co‐formulation of pramlintide and insulin A21G (ADO09) improves post‐prandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes

Pramlintide improves post‐prandial glucose but requires additional injections. This study investigated the pharmacokinetics, pharmacodynamics (PK/PD), efficacy and safety of ADO09, pramlintide/insulin A21G co‐formulation, in T1D. Based on the study findings, in comparison with aspart, ADO09 was well tolerated and effective in T1D across a wide range of dosages, significantly improving the average blood glucose level and body weight during 24 days of ambulatory treatment. Meal test profiles confirmed improvement of glycemic patterns and other responses with ADO09.

  • #family health

Like

Save

Share